+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


The Importance of Board-Level Oversight of a Company’s Compliance Program - Webinar

  • ID: 3734493
  • Webinar
  • June 2016
  • Region: Global
  • 60 Minutes
  • Online Compliance Panel
1 of 3
This session will discuss the need for a company's Board of Directors to be actively engaged in the oversight of the development, implementation, and evaluation of the effectiveness of a company's Corporate Compliance Program. Guidance from the Officer of Inspector General and parallels between OIG expectations and Audit Committee requirements put in place by Sarbanes-Oxley will be discussed as we explore evolving expectations of the appropriate Compliance Program oversight role of their Board.

Objectives of the Presentation

Understand the following:

- OIG Guidance for Boards of Directors on Compliance Oversight
- Corporate Integrity Agreement requirements on Board Oversight Responsibilities
- Parallels with Sarbanes Oxley Audit Committee Requirements
- Board Reliance on Independent Compliance Expertise
- Board Interactions with the Chief Compliance Officer
- Impact of Shareholder Derivative Lawsuits

Why Should you Attend:

It is essential that life sciences companies effectively manage the risks of commercializing a product in a highly regulated environment. Managing risk is the hallmark of an effective Corporate Compliance Program. Over the past several years, the Department of Justice and the Office of Inspector General have recovered billions of dollars from companies accused of violating the Food, Drug and Cosmetic Act, the Anti-Kickback Statute, and the False Claims Act. With its release last year of the Yates Memo, the DOJ upped the ante on the prosecution of individuals within companies. Prosecutions of individuals - including C-suite executives - for bad acts have increased and these acts can jeopardize a company's operations and its reputation. The Board of Directors must understand its role in the oversight the company's Corporate Compliance Program so that it can ensure that the company is taking appropriate steps to protect the company and its personnel.

Who can Benefit:

- Members of healthcare company Boards of Directors
- Outside counsel advising Boards of Directors
- Chief Compliance Officers and their staff
- Chief Risk Officers and their staff
- General Counsel / healthcare compliance legal counsel
- Senior management with Board reporting responsibilities
- Enterprise risk management personnel

Topic Background:

This webinar will provide insight into the role that should be played by a company's Board of Directors in overseeing the development, implementation, and evaluation of the effectiveness of the company's Corporate Compliance Program.
Note: Product cover images may vary from those shown
2 of 3
- Overview of OIG Guidance for Boards Of Directors on Compliance Oversight
- Highlighting CIA requirement
- Demonstrating parallels with Sarbanes Oxley Audit Committee requirements
- Discussing importance of independent compliance expertise
- Exploring how the Board and the Chief Compliance Officer should interact
- Exploring the role of shareholder suits in holding companies accountable
Note: Product cover images may vary from those shown
3 of 3
  • Brian A. Dahl Brian A. Dahl,
    Owner ,
    Dahl Compliance Consulting LLC

    Brian Dahl is the Principal at Dahl Compliance Consulting LLC where his practice focuses on assisting life sciences companies with the development and implementation of their Corporate Compliance Programs. As an in-house compliance professional, he was the architect of the Corporate Compliance Programs at two top tier pharmaceutical companies - Teva Pharmaceuticals and Takeda Pharmaceuticals. As a consultant, Brian has built the Compliance Programs at two start-up pharmaceutical companies that launched their first products during the course of his engagement. Brian published two chapters in an FDLI book entitled Bringing Your Pharmaceutical Drug to Market. His chapters - entitled Developing and Implementing a Corporate Compliance Program and Maturing a Corporate Compliance Program - explore how a company can protect its investment in bringing a drug to market by putting in place the elements of an effective compliance program to manage the risks of moving from development to commercialization. He has authored numerous other articles on various compliance topics and is a frequent speaker on such topics.

Note: Product cover images may vary from those shown